IP Library Granted Patent US 11,255,854
Granted Patent B2
US 11,255,854 · App. 16/359,142 · Granted Feb 22, 2022

Signal amplification in lateral flow and related immunoassays

Inventors: Rajesh K. Mehra (Union City, CA); Kenneth P. Aron (Union City, CA); Dennis M. Bleile (Union City, CA); Jeremy Walker (Union City, CA); Cristina Cuesico (Union City, CA)
Assignee: Zoetis Services LLC
G01N33/54388G01N33/54306G01N33/54313G01N33/54386G01N33/54393G01N33/558G01N33/56911G01N33/56983G01N33/587G01N33/6854G01N33/6857G01N33/6893G01N2333/20G01N2333/29G01N2469/20Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,255,854
App. No.
16/359,142
Granted
Feb 22, 2022
Kind
B2
Abstract

The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays.

Claims (18)

1. A lateral flow assay device comprising

(a) a conjugate region comprising (i) a mobilizable first detector capable of binding to the Fc region of an antibody in a sample, wherein the first detector comprises a protein A and/or protein G, wherein the protein A and/or protein G is conjugated to a gold nanoparticle, and (ii) a mobilizable second detector, wherein the second detector comprises a first antigen or antigenic peptide conjugated to a gold nanoparticle, wherein said first antigen or antigenic peptide is capable of specifically binding to a variable region of the antibody in the sample; and

(b) a test region comprising an immobilized capture entity, wherein the capture entity comprises a second antigen or antigenic peptide, wherein said second antigen or antigenic peptide is capable of specifically binding to the variable region of the antibody in the sample.

2. The lateral flow assay device of claim 1 , wherein the device further comprises a control region comprising an antibody that binds to the first detector.

3. The lateral flow assay device of claim 2 , wherein the antibody that binds to the first detector is an anti-protein A or an anti-protein G antibody.

4. The lateral flow assay of claim 3 , wherein the anti-protein A antibody is a chicken anti-Protein A IgG antibody.

5. The lateral flow assay device of claim 2 , wherein the control region is located on a nitrocellulose membrane.

6. The lateral flow assay device of claim 2 , wherein the test and control regions are located on a nitrocellulose membrane, and wherein the test and control regions do not overlap.

7. The lateral flow assay device of claim 1 , wherein the test region is located on a nitrocellulose membrane.

8. The lateral flow assay device of claim 1 , wherein the conjugate and test regions are in fluid communication such that in operation a liquid sample comprising an antibody flows from the conjugate region to the test region.

9. The lateral flow assay device of claim 1 , wherein the device further comprises a sample loading region, wherein the conjugate region is positioned downstream of the sample loading region.

10. The lateral flow assay device of claim 1 , wherein the device further comprises an absorbent pad positioned downstream of the test region.

11. The lateral flow assay device of claim 1 , wherein said first antigen or antigenic peptide is from an organism selected from the group consisting of heartworm, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys, feline leukemia virus, parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella , adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus.

12. The lateral flow assay device of claim 1 , wherein said second antigen or antigenic peptide is from an organism selected from the group consisting of heartworm, Ehrlichia canis, Ehrlichia chaffeensis, Ehrlichia ewingii, Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, Anaplasma phagocytophilum, Anaplasma platys , feline leukemia virus, parvovirus, influenza A strain, influenza B strain, avian influenza virus, respiratory syncytial virus, Legionella , adenovirus, rotavirus, feline immunodeficiency virus, human immunodeficiency virus, and Group A Streptococcus.

13. The lateral flow assay device of claim 1 , wherein the second detector and the capture entity comprise the same antigen or antigenic peptide.

14. The lateral flow assay device of claim 1 , wherein said first antigen or antigenic peptide and/or said second antigen or antigenic peptide is conjugated to bovine serum albumin (BSA).

15. A kit comprising the lateral flow assay device of claim 1 and instructions for using the device to detect an antibody in a test sample.

16. A method for determining the presence of an antibody in a sample, comprising contacting the test sample with the lateral flow assay device of claim 1 , and detecting the presence of a signal from the test region, wherein the presence of the signal is indicative of the presence of the antibody in the sample.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2021
From: ABAXIS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 055475/0099 →
CHANGE OF NAME Recorded Mar 3, 2021
From: ABAXIS, INC.
To: ABAXIS LLC
Reel/Frame 055475/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: MEHRA, RAJESH K.; ARON, KENNETH P.; BLEILE, DENNIS M.; WALKER, JEREMY; CUESICO, CRISTINA
To: ABAXIS, INC.
Reel/Frame 048648/0792 →
Continuity (5)
Continuation 15886290 · Feb 1, 2018
Division 14688419 · Apr 16, 2015
Division 13682306 · Nov 20, 2012
Provisional Application 61562302 · Nov 21, 2011
Related Publication 20190219572A1 · Jul 18, 2019
Cited By (2)
US 12,416,633 US 12,704,510